Check-cap reports fourth quarter and full year 2021 financial results

Company anticipates initiation of the first part of its u.s. pivotal study in april 2022 isfiya, israel , april 7, 2022 /prnewswire/ -- check-cap ltd. (the "company" or "check-cap") (nasdaq: chek), (nasdaq: chekz), a clinical stage medical diagnostics company advancing the development of c-scan®, the first and only patient-friendly, preparation-free screening test to detect polyps before they may transform into colorectal cancer (crc), today announced financial results for the fourth quarter and full year ended december 31, 2021.
CHEK Ratings Summary
CHEK Quant Ranking